Inovio slips on VGX-3100 clinical hold

Inovio Pharmaceuticals Inc. (NASDAQ:INO) fell $1.37 (16%) to $6.99 on Monday after it said FDA placed a clinical hold on the company's planned Phase III study of VGX-3100 to treat cervical intraepithelial neoplasia (CIN) associated with HPV types 16 or 18. Inovio now expects the study to begin in 1H17. It had hoped to start it by YE16.

The company said FDA requested additional data concerning the shelf life of its redesigned Cellectra electroporation device, which is associated with the candidate's administration. Inovio said it believes the relevant data will be available this year. ...